Hannah Asghari, M.D.
Medical Oncologist and Hematologist
4.9 (223 RATINGS)
Clinical Expertise
Medical Oncology
Appointments
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
I am dedicated to providing exceptional patient-centered care.
Hannah Asghari, M.D., is a high-achiever noted for academic scholarship and dedication to her patients. A board-certified physician specializing in hematology and oncology, Dr. Asghari feels “deeply privileged to help guide patients during their most trying times.”
Dr. Asghari is a summa cum laude graduate of University of Florida, where she studied biochemistry and molecular biology. She received her medical degree at UF and continued her training at Johns Hopkins Hospital in Baltimore, followed by a hematology/oncology fellowship at University of South Florida based at Moffitt Cancer Center in Tampa, Florida.
Dr. Asghari says she’s known “since childhood” that she wanted to be a physician. She’s delighted to join the City of Hope family. “City of Hope,” she said, “is on the cutting edge of research and provides outstanding patient care.”
Dr. Asghari is a summa cum laude graduate of University of Florida, where she studied biochemistry and molecular biology. She received her medical degree at UF and continued her training at Johns Hopkins Hospital in Baltimore, followed by a hematology/oncology fellowship at University of South Florida based at Moffitt Cancer Center in Tampa, Florida.
Dr. Asghari says she’s known “since childhood” that she wanted to be a physician. She’s delighted to join the City of Hope family. “City of Hope,” she said, “is on the cutting edge of research and provides outstanding patient care.”
2020, American Board of Medical Oncology
2020, American Board of Hematology
2017, American Board of Internal Medicine
2014, M.D., Doctor of Medicine, University of Florida, Gainesville, FL
2009, B.S., Bachelor of Science, University of Florida, Gainesville, FL
2017-2020, Fellow, Hematology and Oncology, University of South Florida/Moffitt Cancer Center, Tampa, FL
2014-2017, Resident, Internal Medicine, Johns Hopkins Hospital, Baltimore, MD
2020-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Antelope Valley, CA
2019, American Society of Hematology Abstract Achievement Award
2019, Moffitt Scientific Symposium Featured Poster Presentation Award
2014, Caranasos Medical Student Professionalism Award
2013, Gold Humanism Honor Society
2013, UF College of Medicine Alumni Scholarship for Academic Excellence
2007, Distinguished Anderson Scholar
2020, American Society of Clinical Oncology
2020, American Society of Hematology
1. Asghari H, Talati C. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. Current Opinion in Hematology. 9000; Publish Ahead of Print. DOI: 10.1097/MOH.0000000000000568.
2. Asghari, H. and Lancet, J. E. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Leukemia & Lymphoma. 2020:1-8. DOI:10.1080/10428194.2020.1719093.
3. Asghari H, Mo Q, Naqvi SM, Nishihori T, Hansen D, Ahmad A, Elmariah H, Lazaryan A, Davilla M, Faramand R, Khimani F, Mishra A, Perez L. Nieder M, Pidala J, Anasetti C, Bejanyan N. Composite Disease Risk Comorbidity Index (DRCI) Predicts Survival of Older Adults with AML or MDS Receiving Allogeneic Hematopoietic Cell Transplantation (In Submission).
Abstracts and Poster Presentations
1. Asghari H, Mo Q, Naqvi SM, Lazaryan A, Davila ML, Nishihori T, Khimani F, Mishra A, Perez LE, Elmariah H, Liu H, Nieder M, Fernandez H, Pidala JA, Anasetti C, Bejanyan N. (2019). Survival of Older Patients with AML and MDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices. 2019 Transplantation & Cellular Therapy Meeting of ASBMT and CIBMTR. Biology of Blood and Marrow Transplantation, 25(3), S124-S125.
DOI:10.1016/j.bbmt.2018.12.406
2. Asghari H, Talati C, Achille A, Powers J, Sahakian E, Chan O, Isenalumhe L, Nodzon L, Sweet K, Pinilla-Ibarz J. (2019). Comparison of Digital Droplet Polymerase Chain Reaction (ddPCR) Technology to Real Time Quantitative PCR (RT-qPCR) for Detection of BCR-ABL p210 Transcript upon Tyrosine Kinase Inhibitor Discontinuation in Patients with CP-CML. 21ST Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. Bordeaux, France, September 12-15, 2019.
3. Chan O, Jennings M, Asghari H, Song J, Hussaini M, Sallman D, Padron E, Komrokji R, List A, Lancet J, Mishra A, Sweet K, Talati C. (2019). RUNX1 Mutation is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia (AML) who Received Allogeneic Stem Cell Transplantation (allo-SCT). 2019 Society of Hematologic Oncology Annual Meeting. Clinical Lymphoma, Myeloma and Leukemia, 19, S233. DOI:10.1016/j.clml.2019.07.119
4. Asghari H, Lee D, Deutsch YE, Chan O, Al Ali N, Boisclair S, Brahim A, Padron E, Kuykendall A, List A, Fernandez H, Lancet J, Sallman D, Komrokji R, Sweet K, Talati C. HANNAH H. ASGHARI, M.D. PAGE 3 (2019). Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 1357-1357. DOI:10.1182/blood-2019-128958
5. Asghari H, Lee D, Deutsch YE, Chan O, Al Ali N, Boisclair S, Terrell C, Padron E, Kuykendall A, List A, Fernandez H, Lancet J, Sallman D, Komrokji R, Sweet K, Talati C. (2019). Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 3895-3895. DOI:10.1182/blood-2019-130379
6. Asghari H, Talati C, Achille A, Powers JJ, Sahakian E, Chan O, Shelton D, Isenalumhe L, Nodzon L. Sweet K, Pinilla Ibarz J. (2019). Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 3382-3382. DOI: 10.1182/blood-2019-131207
7. Chan O, Hunter A, Talati C, Sallman DA, Asghari H, Song J, Hussaini M, Bejanyan N, Elmariah H, Kuykendall A, Padron E, Komrokji R, List A, Lancet J, Sweet K, Mishra A. (2019). Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 149-149. DOI:10.1182/blood-2019- 131530
8. Chan O, Talati C, Asghari H, Bejanyan N, Elmariah H, Hussaini M, Khimani F, Kim J, Komrokji R, Kuykendall A, Lancet J, List A, Nieder M, Nishihori T, Padron E, Perez L, Pidala J, Song J, Zhou J, Sallman D. Sweet K, Mishra A. (2019). Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 4621-4621. DOI:10.1182/blood-2019-130922
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
4.9
Show respect for what you say
4.9
Spend enough time with you
4.9
Recommend this provider office
4.9
Provider listen carefully to you
4.8
Know important info medical history
4.8
Rate provider 0-10
4.8
Provider explain in way you understand
Reviews
02/02/23
Greatest care givers! - Verified patient
01/31/23
Thorough, thoughtful and patient. - Verified patient
01/31/23
A very good experience. - Verified patient
01/31/23
First class health care and communication. - Verified patient
01/27/23
A great doctor. - Verified patient